Well-Rehearsed Valeant Call Unlikely To Stop Deeper Probes
This article was originally published in The Pink Sheet Daily
Executive Summary
Valeant starts to provide some answers, but questions over pricing and specialty pharmacy relationships will continue. Firm is setting up an ad hoc committee, although others would prefer an independent audit.